A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers

Pfizer

Status: Completed

Conditions: Healthy

Treatments: Drug: Ritalin; Drug: Placebo

Study type: Observational

Funder types: Industry

Identifiers

NCT02265718

A9001489

Details and patient eligibility

About

The purpose of the study is to evaluate the difference in learning and performance measures associated with repeated use of an iPad video game (Akili Interactive's Project: EVO) in healthy elderly volunteers based on amyloid status.

Enrollment: 97 patients

Sex: All

Ages: 70 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males and females between the ages of 70 and 80.
• Subjects must have BMI of 17.5 to 32 kg/m2 and total body weight > 110 pounds.
• Acceptable screening MRI and PET scans that pass quality control requirements.

Exclusion criteria

• Co-morbid diagnosis of clinically documented Alzheimer's disease; - Significant cognitive impairment;
• MMSE (mini mental state examination) score <26

Trial design

97 participants in 2 patient groups

(Amyloid Negative)

Treatment:

Drug: Placebo

Drug: Placebo

Drug: Ritalin

Drug: Ritalin

Amyloid Positive

Treatment:

Drug: Placebo

Drug: Placebo

Drug: Ritalin

Drug: Ritalin